Skip to content
Home/Companies/Biotech/Novexel

Novexel

Biotech·France·Exited 2010·Held 4yr
Entry
2006
Hold
4yr
Exit
2010

Who owns Novexel?

Novexel is a French Biotech company, now owned by AstraZeneca, which acquired it in 2010 from Sofinnova Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VI · 2008 · Life Sciences VC

Key facts

HQFrance
SectorBiotech
Exit Type
Trade Sale
Buyer
AstraZeneca
Exit Year
2010

More from Sofinnova Capital VI

Other portfolio companies in the same fund.

ABIONYX Pharma
Exited 2020
BiotechFrance· 2010
DBV
Exited 2014
BiotechFrance· 2010
Omthera Pharmaceuticals
Exited 2013
BiotechUS· 2010
to AstraZeneca
Ablynx NV
Exited 2018
BiotechBelgium· 2008
to Sanofi
Addex Therapeutics
Exited 2012
BiotechSwitzerland· 2008
Movetis
Exited 2010
BiotechBelgium· 2008
to Shire

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Novexel?

Novexel is now owned by AstraZeneca, which acquired it in 2010 from Sofinnova Partners.

When did AstraZeneca acquire Novexel?

AstraZeneca acquired Novexel in 2010, buying from Sofinnova Partners.

Who did Novexel sell to?

Sofinnova Partners sold Novexel to AstraZeneca in 2010 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue